Page 13 - Pure Tech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Peugeot 308 - Back to Basics Peugeot houdt ervan om zijn modellen zonder meerprijs in een opvallende kleur te leveren. Laat je het kleurenpalet links liggen, dan rolt de 208 in het geel de spuitcabine uit en ook de 2008 heeft standaard een opvallend kleurtje. De nieuwe 308 doet vrolijk mee met het opvallende 'Vert Olivine', maar staat het licht ook op groen voor het uitrustingsniveau van de basisversie? Dat zoeken we vandaag uit. Peugeot 308 1.2 PureTech 110 Active Pack Business € 27.790 Niet alleen de kleur van de nieuwe 308 valt op. De C-segmenter heeft een veel agressiever voorkomen dan ...

PureTech Health plc: PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the formation of its Clinical Advisory Board for idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung d...

Citroen has gone back to the future with its new flagship C5X - a car fit for the French President or a family - and with a boot big enough to carry a washing machine. Drawing on Citroen's rich heritage of large luxury cars that waft the driver and passenger along on 'magic carpet ride' suspension, the C5X takes inspiration from the legendary DS and the subsequent CX, XM and most recent C6. Rolling the dice with what it sees as an update to the concept of the big saloon for the modern age, the French carmaker says the C5X is a stylish fastback mix of saloon, SUV and estate with a keen eye on ...

Pfizer pours $25m into Vedanta's Phase II IBD study The pharma giant has invested in the clinical trial exploring the viability of Vedanta Biosciences’ VE202 inflammatory bowel disease treatment candidate. PureTech Health, a clinical-stage biotherapeutics firm, has announced its Vedanta Biosciences founded entity has landed a $25m (20.6 EUR) investment as part of the Pfizer Breakthrough Growth Initiative (PGBI). Vedanta plans to use the money to fund its Phase II study of VE202 to treat inflammatory bowel disease (IBD), scheduled to launch in 2021. A Vedanta spok...